Trial reportBMC gastroenterology2010
A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial.
Trial report in BMC gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00355810 (Lactobacillus Plantarum MF 1298 vs Placebo for Irritable Bowel Syndrome.), which is not on this map. Cited by 47 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Lactobacillus Plantarum MF 1298 vs Placebo for Irritable Bowel Syndrome.
Who cites it
47 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- The Health Benefits of Probiotic Lactiplantibacillus plantarum: A Systematic Review and Meta-Analysis.Probiotics and antimicrobial proteins · 2025Pooled it
- Pooled it
- Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.Frontiers in cellular and infection microbiology · 2022Pooled it
- Alterations of Gut Microbiota in Patients With Irritable Bowel Syndrome Based on 16S rRNA-Targeted Sequencing: A Systematic Review.Clinical and translational gastroenterology · 2019Pooled it
- A Systematic Review of Probiotic Interventions for Gastrointestinal Symptoms and Irritable Bowel Syndrome in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).Probiotics and antimicrobial proteins · 2018Pooled it
- Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus.Alimentary pharmacology & therapeutics · 2018Pooled it
- Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.World journal of gastroenterology · 2015Pooled it
- Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice -- an evidence-based international guide.Alimentary pharmacology & therapeutics · 2013Pooled it
- Guideline
- Safety ofNutrients · 2026Trial
- Efficacy and dose response ofWorld journal of gastroenterology · 2023Trial
- Co-Administration of Soy Isoflavones and Vitamin D in Management of Irritable Bowel Disease.PloS one · 2016Trial
- Trial
- State-of-the-Art Review on Probiotics, Synbiotics, and Microbial Metabolites: Molecular Mechanisms Shaping Host Immunity, Metabolic Health, and Chronic Disease Prevention.Molecular nutrition & food research · 2026Review
- Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.Journal of clinical medicine · 2026Review
- Metabolomic and functional profiling of Lactiplantibacillus plantarum strains reveals distinct probiotic, immunomodulatory, and antimicrobial signatures.Applied microbiology and biotechnology · 2026Article
- Oral Biofilm Composition, Dissemination to Keratinocytes, and Inflammatory Attenuation Depend on Probiotic and Synbiotic Strain Specificity.Probiotics and antimicrobial proteins · 2025Article
- Strain-Specific Therapeutic Potential ofNutrients · 2025Article
- Probiotics and Prebiotics for the Treatment of Irritable Bowel Syndrome-A Narrative Review.Journal of clinical medicine · 2024Review
- A Meta-analysis of the Effect of ProbioticMedeniyet medical journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSome probiotics have shown efficacy for patients with irritable bowel syndrome (IBS). Lactobacillus (L.) plantarum MF1298 was found to have the best in vitro probiotic properties of 22 strains of lactobacilli. The aim of this study was to investigate the symptomatic effect of L. plantarum MF1298 in subjects with IBS. Primary outcome was treatment preference and secondary outcomes were number of weeks with satisfactory relief of symptoms and IBS sum score.
methodsThe design was a randomised double blind placebo-controlled crossover trial. 16 subjects with IBS underwent two three-week periods of daily intake of one capsule of 10(10) CFU L. plantarum MF 1298 or placebo separated by a four-week washout period.
resultsThirteen participants (81%; 95% CI 57% to 93%; P = 0.012) preferred placebo to L. plantarum MF1298 treatment. The mean (SD) number of weeks with satisfactory relief of symptoms in the periods with L. plantarum MF1298 and placebo were 0.50 (0.89) and 1.44 (1.26), respectively (P = 0.006). IBS sum score was 6.44 (1.81) in the period with L. plantarum MF1298 treatment compared with 5.35 (1.77) in the period with placebo (P = 0.010). With a clinically significant difference in the IBS sum score of 2 in disfavour of active treatment, the number needed to harm was 3.7, 95% CI 2.3 to 10.9.
conclusionsThis trial shows for the first time an unfavourable effect on symptoms in subjects with IBS after intake of a potential probiotic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.